Our findings on the B16 melanoma model indicate that NLRC5 expression in APCs alone is not sufficient to induce antitumor immunity, and that NLRC5 expression in tumor cells is crucial to elicit antitumor immune response, which was also effective against parental B16 cells that display reduced MHC-I expression [29]. This evidence concerns the gene NLRC5 and neoplasm.